Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancer by Natasha B. Hunter, Lanell M. Peterson, Jennifer M. Specht, David A. Mankoff, Mark Muzi, Delphine L. Chen, William R. Gwin, Shaveta Vinayak, Nancy E. Davidson, Hannah M. Linden

Get full text

Repeatability of 18F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trials by Mark Muzi, Lanell M. Peterson, Jennifer M. Specht, Daniel S. Hippe, Alena Novakova-Jiresova, Jean H. Lee, Brenda F. Kurland, David A. Mankoff, Nancy Obuchowski, Hannah M. Linden, Paul E. Kinahan

Get full text

Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer by Anum S. Kazerouni, Lanell M. Peterson, Isaac Jenkins, Alena Novakova-Jiresova, Hannah M. Linden, Julie R. Gralow, David M. Hockenbery, David A. Mankoff, Peggy L. Porter, Savannah C. Partridge, Jennifer M. Specht

Get full text

AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer by Aditya Bardia, Sarat Chandarlapaty, Hannah M. Linden, Gary A. Ulaner, Alice Gosselin, Sylvaine Cartot-Cotton, Patrick Cohen, Séverine Doroumian, Gautier Paux, Marina Celanovic, Vasiliki Pelekanou, Jeffrey E. Ming, Nils Ternès, Monsif Bouaboula, Joon Sang Lee, Anne-Laure Bauchet, Mario Campone

Get full text